Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries

• Status: Recruiting
• Trial end date: 2022-01-15
• Target enrollment: 0
• Participant gender: All

Summary

Combined spinal epidural anesthesia (CSE) with bupivacaine alone is not sufficient to cover pain sequel during lower limb surgeries.

Previous studies used addition of either Nalbuphine or dexmedetomidine to bupivacaine in epidural anesthesia giving a good result in pain control.

In this study the investigators will evaluate and compare the addition of either Nalbuphine or dexmedetomidine to bupivacaine in epidural anesthesia to evaluate the analgesic efficacy of either drug.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Dexmedetomidine; Nalbuphine

Criteria

Inclusion Criteria:

• patient acceptance.

• BMI 25-29.9 kg/m2.

• ASA I and ASA II.

• Scheduled for elective lower limb orthopedic surgeries under (CSE) block.

Exclusion Criteria:

• Patient with known allergy to study drugs,

• Patients suffering from severe chronic diseases (cardiac, renal, hepatic and neurological or diabetes),

• Patients with infection at the site of spinal-epidural block,

• Drug addict patients,

• Patients on long term steroid therapy,

• Patients with abnormalities in vertebral spine,

• Mentally retarded or uncooperative patients,

• Patients receive anti-coagulant therapy or suspected coagulopathy.